Compare SCD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCD | FHTX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.4M | 246.6M |
| IPO Year | N/A | 2020 |
| Metric | SCD | FHTX |
|---|---|---|
| Price | $14.88 | $4.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.83 |
| AVG Volume (30 Days) | 62.6K | ★ 207.6K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,518,000.00 |
| Revenue This Year | N/A | $42.43 |
| Revenue Next Year | N/A | $14.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.33 | $2.95 |
| 52 Week High | $15.87 | $8.08 |
| Indicator | SCD | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 48.26 |
| Support Level | $14.65 | $4.40 |
| Resistance Level | $14.94 | $4.87 |
| Average True Range (ATR) | 0.23 | 0.37 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 93.04 | 14.33 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.